Literature DB >> 10620325

Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1.

S Ito1, T Nemoto, S Satoh, H Sekihara, Y Seyama, S Kubota.   

Abstract

We evaluated the expression of glucose transporter (glut) isoforms and its function in RD cells, human rhabdomyosarcoma, which retain the potential to differentiate into muscle. Gluts 1, 3, and 4 were expressed in RD cells, as detected by reverse-transcription polymerase chain reaction and immunocytochemistry. Supraphysiological concentration (1 microM) of insulin treatment increased 2-deoxy glucose transport by up to 1.68-fold together with concomitant tyrosine phosphorylation of the insulin receptor beta subunit and of insulin receptor substrate 1. Suppression of glut 1 mRNA by 38% by antisense oligonucleotide transfection led to a reduction of basal and insulin-stimulated 2-deoxy glucose transport by 38 and 55%, respectively. Suppression of gluts 3 and 4 by antisense oligonucleotide transfection did not affect both basal and insulin-stimulated 2-deoxy glucose transport. Thus, glut 1 accounts for the major part of basal and insulin-stimulated glucose transport in RD cells. Next, we transfected expression vectors carrying human gluts 1 and 4 cDNAs into RD cells to add further support for the role of glut 1 in glucose transport. Overexpression of glut 1 stimulated basal and insulin-stimulated 2-deoxy glucose transport by 1.66- and 1.43-fold, respectively. Glut 4 overexpression did not affect basal and insulin-stimulated 2-deoxy glucose transport. Western blot analysis using glut 1 antibody showed that glut 1 was redistributed from intracellular membrane to plasma membrane. These observations support the notion that RD cells, with the potential to differentiate into muscle, retain insulin responsiveness. As human muscle cell lines are not available at this point, RD cells can serve as a useful alternative to human muscle for studies related to insulin signal transduction and glucose transport. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620325     DOI: 10.1006/abbi.1999.1535

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.

Authors:  Ukihide Tateishi; Umio Yamaguchi; Kunihiko Seki; Takashi Terauchi; Yasuaki Arai; Tadashi Hasegawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-28       Impact factor: 9.236

2.  Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.

Authors:  Adrien Daigeler; Daigeler Adrien; Ludger Klein-Hitpass; Klein-Hitpass Ludger; Ingo Stricker; Stricker Ingo; Oliver Müller; Müller Oliver; Cornelius Kuhnen; Kuhnen Cornelius; Ansgar Michael Chromik; Chromik Ansgar Michael; Lars Steinstraesser; Steinstraesser Lars; Ole Goertz; Goertz Ole; Hans-Ulrich Steinau; Steinau Hans-Ulrich; Marcus Lehnhardt; Lehnhardt Marcus
Journal:  Langenbecks Arch Surg       Date:  2009-01-22       Impact factor: 3.445

3.  Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model.

Authors:  Christy A Rothermund; Velliyur K Gopalakrishnan; James D Eudy; Jamboor K Vishwanatha
Journal:  BMC Urol       Date:  2005-03-24       Impact factor: 2.264

4.  Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma.

Authors:  Sen-Xiang Yan; Xing-Mei Luo; Shui-Hong Zhou; Yang-Yang Bao; Jun Fan; Zhong-Jie Lu; Xin-Biao Liao; Ya-Ping Huang; Ting-Ting Wu; Qin-Ying Wang
Journal:  Int J Med Sci       Date:  2013-08-21       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.